Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy

Joint Bone Spine

Volumn 76, Issue 3, 2009, Pages 308-311

  Wendling, Daniel ^a,b   Di Martino, Vincent ^a,b   Prati, Clément ^a,b   Toussirot, Eric ^a,b   Herbein, Georges ^b,c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL SAINT JACQUES   (France)

Author keywords

Chronic hepatitis B; Spondyloarthropathy; TNF antagonists

Indexed keywords

ADALIMUMAB; ADEFOVIR; ETANERCEPT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PATIENT MONITORING; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; LAMIVUDINE; MALE; METHOTREXATE; PHOSPHONIC ACIDS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS ACTIVATION;

EID: 67349155253     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.11.005     Document Type: Article

References (13)

1. Wendling D., and Herbein G. TNFalpha antagonist therapy in patients with joint disease and chronic viral infection. Joint Bone Spine 74 (2007) 407-409
2. Wendling D., Auge B., Bettinger D., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64 (2005) 788-789
3. Carroll M.B., and Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38 (2008) 208-217
4. Roux C.H., Brocq O., Breuil V., et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 45 (2006) 1294-1297
5. Oniankitan O., Duvoux C., Challine D., et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31 (2004) 107-109
6. Sakellariou G.T., and Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26 (2007) 950-952
7. Cansu D.U., Kalifoglu T., and Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35 (2008) 421-424
8. Ozorio G., McGarity B., Bak H., et al. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187 (2007) 524-526
9. García Aparicio A.M., Rey J.R., Sanz A.H., et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26 (2007) 811-813
10. Thiéfin G., Morelet A., Heurgué A., et al. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 15 (2008) 737-739
11. Calabrese L.H., Zein N.N., and Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65 (2006) 983-989
12. Nathan D.M., Angus P.W., and Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21 (2006) 1366-1371
13. Pham T., Claudepierre P., Deprez X., et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 72 Suppl. 1 (2005) S1-58